We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

EKF Diagnostics

Manufactures analysers for the measurement of glucose, lactate, hemoglobin, hematocrit and HbA1c for GP surgeries, ph... read more Featured Products: More products

Download Mobile App





EKF Diagnostics Highlights Assay for Diabetes Patient Monitoring

By LabMedica International staff writers
Posted on 06 Aug 2019
Global in vitro diagnostics company EKF Diagnostics (Penarth, Cardiff, UK) showcased its liquid, enzymatic test for glycated albumin (GA) at the 71st AACC Annual Scientific Meeting & Clinical Lab Expo held on August 4-8, at the Anaheim Convention Center in California, USA. More...
The GA test, which was recently FDA cleared for sales in the U.S, is used for intermediate term monitoring of glycemic control in diabetes patients. EKF is the exclusive distributor of the Lucica Glycated Albumin-L test manufactured by Asahi-Kasei Pharma Corporation of Japan.

The Lucica Glycated Albumin-L test is intended for use for the quantitative measurement of GA in human serum on compatible clinical chemistry analyzers with open channel capability. It specifically measures both glycated albumin (enzymatic) and total albumin (BCP) in separate reactions. Results are expressed as a ratio (%) of glycated albumin to total albumin, thus minimizing differences in protein concentrations between patients. Visitors to EKF Diagnostics’ booth also had the opportunity to meet the inventor of this enzymatic method for GA, Takuji Kohzuma Ph.D, Chief Researcher, Diagnostics and Clinical Development for Asahi Kasei Pharma Corporation. For the development of this methodology, Dr. Kohzuma was awarded the ‘Prize of Technology’ by the Japanese Society of Clinical Chemistry in 2005. The Lucica GA has been one of the most widely used and published enzymatic GA methods in the world.

At AACC 2019, EKF Diagnostics also showcased some of its other clinical chemistry focused products, including another key assay in its portfolio, the Beta-Hydroxybutyrate LiquiColor Assay (B-HB). The LiquiColor B-HB test features liquid, ‘ready to use’ reagents and is intended for the quantitative measurement of B-HB with serum or plasma on compatible clinical chemistry analyzers with open channel capability.

EKF Diagnostics’ central laboratory and point-of-care (POC) analyzers were also on display at this year’s AACC, including the Altair 240, a fully-automated bench-top clinical chemistry analyzer, and the HemoPoint H2 POC analyzer that is designed to rapidly provide quantitative, lab quality hemoglobin and hematocrit results from a single drop of blood. At AACC 2019, EKF Diagnostics exhibited Hemo Control, a point-of-care hemoglobin analyzer designed to provide quantitative, lab quality hemoglobin results from 25 seconds, and DiaSpect Tm, the world’s fastest hemoglobin analyzer that delivers laboratory quality results in just about one second of the microcuvette being placed into the analyzer. The company also showcased Quo-Test, a fully automated desktop POC analyzer designed for easy and reliable HbA1c measurement, and Creamatocrit Plus, the first and only system dedicated to providing a fast, accurate creamatocrit measure in mother’s milk.


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Serological Pipet Controller
PIPETBOY GENIUS
New
Glucose Tolerance Test
NERL Trutol
New
Toxoplasma Gondii Test
Toxo IgG ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.